<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="780">
  <stage>Registered</stage>
  <submitdate>22/09/2005</submitdate>
  <approvaldate>5/10/2005</approvaldate>
  <actrnumber>ACTRN12605000597695</actrnumber>
  <trial_identification>
    <studytitle>Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The Einstein-DVT dose-finding study.</studytitle>
    <scientifictitle>Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis to assess the dose-effect relationship and determine the optimum dose.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Einstein</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute symptomatic deep-vein thrombosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To assess the dose-effect relationship of once-daily BAY 59-7939 in the treatment of patients with acute symptomatic deep-vein thrombosis (DVT) using the combination of (LMW) heparin and vitamin K antagonist (VKA) as comparator.
To determine the optimum once daily dose of BAY 59-7939 for use in phase III studies.
 
Patients will receive either BAY 59-7939 (20, 30 or 40 mg, once-daily) or the combination of (LMW) heparin/VKA (INR 2.0-3.0). The study duration is 12 weeks followed by an additional observational period of 30 days.</interventions>
    <comparator>Combination of (low molecular weight) heparin and vitamin K antagonist (VKA) given subcutaneously in doses to provide an International Normaised Ratio (INR) of 2.0 - 3.0.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. Symptomatic recurrent DVT or symptomatic fatal or non-fatal pulmonary embolism (PE) </outcome>
      <timepoint>At week 12.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Deterioration of the thrombotic burden as assessed by repeat compression ultrasound (CUS) and perfusion lung scan (PLS).</outcome>
      <timepoint>At week 12.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The principal safety outcome is the combination of major and clinically relevant non-major bleeding.</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The separate components of the primary efficacy outcome.</outcome>
      <timepoint>At 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Confirmed acute symptomatic DVT, i.e., proximal or extensive calf-vein thrombosis, involving at least the upper third part of the calf veins without concomitant symptomatic PE 2. Written informed consent. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Under 18 years of age.2. Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of  DVT3. Other indication for VKA than DVT4. More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW) heparin or more than a single dose of VKA prior to randomization5. Participation in another pharmacotherapeutic study within 30 days6. Creatinine clearance &lt; 30 ml/min, impaired liver function (transaminases &gt; 2 x ULN), or bacterial endocarditis7. Life expectancy &lt;3 months8. Active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin 9. Uncontrolled hypertension: systolic blood pressure &gt;200 mmHg and diastolic blood pressure &gt;110 mmHg10. Pregnancy or childbearing potential without proper contraceptive measures11. Any other contraindication listed in the local labeling of warfarin, acenocoumarol, phenprocoumon, fluidione, UFH, enoxaparin, or tinzaparin 12. Systemic treatment with azole compounds or other strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazol, itraconazol, HIV protease inhibitors) within 4 days prior to randomization and during the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Done centrally by interactive voice response system.</concealment>
    <sequence>Computer generated random code.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>520</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer Australia Ltd</primarysponsorname>
    <primarysponsoraddress>875 Pacific Highway, Pymble NSW 2073</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer Australia Ltd</fundingname>
      <fundingaddress>875 Pacific Highway, Pymble NSW 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Services Manager</name>
      <address>Bayer Australia
PO Box 903
Pymble NSW 2073</address>
      <phone>+61 2 93916140</phone>
      <fax />
      <email>@bayerhealthcare.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Research Manager</name>
      <address>Bayer Australia
PO Box 903
Pymble NSW 2073</address>
      <phone>+61 2 93916140</phone>
      <fax />
      <email>@bayerhealthcare.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>